maintenance therapy with revumenib following allosct in kmt2ar and npm1-mutated acute leukemias
Published 5 months ago • 124 plays • Length 3:52Download video MP4
Download video MP3
Similar videos
-
1:48
do all patients require maintenance therapy following allosct?
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
2:03
maintenance therapy in aml
-
1:19
astx727 a molecularly-targeted agent as personalized maintenance therapy in patients with aml
-
8:21
quazar aml-001: a new standard for aml maintenance therapy
-
4:08
cc-486 maintenance therapy in aml
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:11
dr lai on nccn guideline updates in aml maintenance therapy
-
1:44
improving maintenance therapy in aml: exploring the role of idh inhibitors
-
5:31
how does maintenance therapy benefit patients with aml? #aml
-
1:40
the role of menin inhibitors in the treatment of aml
-
1:57
glasdegib as maintenance therapy in aml and mds
-
2:45
continuity of care for patients with hematological predispositions to aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
14:43
current research into post-allosct maintenance therapy in aml
-
2:49
maintenance therapy in aml: agents under investigation and future outlooks
-
1:06
lenalidomide: should maintenance therapy after autograft be limited?